查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1608028

人类绒毛膜促性腺激素分泌市场：按产品、治疗领域和最终用户 - 2025-2030 年全球预测

Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，人类绒毛膜促性腺激素分泌市值为12.7亿美元，预计2024年将达到13.7亿美元，复合年增长率为7.53%，到2030年将达到21.1亿美元。

人类绒毛膜促性腺激素分泌（HCG）是怀孕期间胎盘产生的一种激素，对胎儿发育起着重要作用。在市场研究中，观察到 HCG 在不孕症治疗、体重管理治疗和妊娠检测诊断应用方面具有商业性应用。对 HCG 的需求主要在于透过其在体外受精 (IVF) 等辅助生殖技术 (ART) 中的使用来协助生殖健康。 HCG 的医疗用途不仅限于不孕症治疗，而且由于它存在于某些类型的癌症中，因此也在肿瘤检测和管理等领域进行研究。最终用途范围包括生育诊所、实验室、製药公司和诊断中心。

主要市场统计
基准年[2023] 12.7亿美元
预测年份 [2024] 13.7亿美元
预测年份 [2030] 21.1亿美元
复合年增长率（%） 7.53%

影响 HCG 市场的主要成长要素包括不孕症盛行率的增加、生殖健康意识的增强以及生物技术的进步促进创新治疗方案。此外，对快速诊断试剂套件的需求不断增长也推动了市场的发展。扩大 HCG 在肿瘤学中的应用范围并开发体重管理製剂可能为治疗方法开发铺平道路。然而，监管障碍、道德考量和不孕症治疗的高成本等挑战可能会构成重大限制并抑制市场成长。社会文化因素，包括与不孕症治疗相关的耻辱，也可能阻碍市场采用。

对于技术创新和业务成长，专注于精准医疗和HCG生化途径的研究并扩大其治疗应用可能会增强市场活力。此外，可以透过投资具有成本效益的治疗方法以及在生物技术公司、研究机构和医疗保健提供者之间建立强大的合作网络来扩大市场渗透率。 HCG 市场的本质是动态的，基因研究和生物製造的创新为演化提供了潜在的催化剂。了解消费者需求、利用新的生物技术和促进道德透明度可以引导市场相关人员实现永续成长和竞争优势。

市场动态：揭示快速发展的人类绒毛膜促性腺激素分泌市场的关键市场洞察

供需的动态交互作用正在改变人类绒毛膜促性腺激素分泌市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 不孕人口增加
    • 加大对生育诊所发展的投资
    • 提高不孕症治疗意识
  • 市场限制因素
    • 人类绒毛膜促性腺激素分泌治疗的高成本
  • 市场机会
    • 基因重组技术的进展
    • 促性腺激素分泌疗法在医疗保健领域的出现
  • 市场挑战
    • 人类绒毛膜促性腺激素分泌治疗可能产生的副作用

波特的五力：驾驭人类绒毛膜促性腺激素分泌市场的策略工具

波特的五力框架是了解人类绒毛膜促性腺激素分泌市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对人类绒毛膜促性腺激素分泌市场的外部影响

外部宏观环境因素在塑造人类绒毛膜促性腺激素分泌市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解人类绒毛膜促性腺激素分泌市场的竞争格局

对人类绒毛膜促性腺激素分泌市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类绒毛膜促性腺激素分泌市场供应商的绩效评估

FPNV 定位矩阵是评估人类绒毛膜促性腺激素分泌市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製人类绒毛膜促性腺激素分泌市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对人类绒毛膜促性腺激素分泌市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 不孕不育人口增加
      • 加大生育诊所建设投入
      • 提高不孕症治疗意识
    • 抑制因素
      • 人类绒毛膜促性腺激素分泌治疗的高成本
    • 机会
      • 重组技术的进展
      • 促性腺激素分泌疗法在医疗保健领域的出现
    • 任务
      • 人类绒毛膜促性腺激素分泌治疗可能产生的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章人类绒毛膜促性腺激素分泌市场：副产品

  • 自然提取
  • 重组

第七章依治疗领域分類的人类绒毛膜促性腺激素分泌市场

  • 女性不孕症治疗
  • 男性性腺功能低下症
  • 少精症的治疗

第八章 人类绒毛膜促性腺激素分泌市场：依最终用户分类

  • 不孕不育治疗诊所
  • 调查机构

第九章北美和南美人绒毛膜促性腺激素分泌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区人类绒毛膜促性腺激素分泌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲人绒毛膜促性腺激素分泌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Biocare Medical, LLC
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Ferring BV
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Kamia Biomedical Company
  • Lee Biosolutions, Inc.
  • Life Medicare & Biotech Private Limited
  • Livzon Pharmaceutical Group Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Prospec-Tany Technogene Ltd.
  • Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
  • Sanzyme（P）Ltd.
  • Scripps Laboratories, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sunrise International Labs Ltd.
Product Code: MRR-6108DAA288C5

The Human Chorionic Gonadotropin Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.37 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 2.11 billion by 2030.

Human Chorionic Gonadotropin (HCG) is a hormone produced during pregnancy by the placenta, playing a critical role in fetal development. In the market research context, HCG is observed for its commercial applications in fertility treatments, weight management therapies, and its diagnostic use in pregnancy tests. The necessity for HCG hinges on its application in assisting reproductive health, primarily through its use in assisted reproductive technologies (ART) like in-vitro fertilization (IVF). Its medical applications extend beyond fertility, as it's being researched in areas such as tumor detection and management due to its presence in certain cancer types. The end-use scope covers fertility clinics, research laboratories, pharmaceutical companies, and diagnostic centers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.37 billion
Forecast Year [2030] USD 2.11 billion
CAGR (%) 7.53%

Key growth factors influencing the HCG market include the increasing prevalence of infertility, rising awareness regarding reproductive health, and advancements in biotechnology facilitating innovative treatment options. Additionally, the market is propelled by the growing demand for rapid diagnostic kits. A potential opportunity lies in expanding the scope of HCG applications in oncology and developing its formulations to address weight management, opening streams for therapeutic developments. However, challenges such as regulatory hurdles, ethical considerations, and the high cost of fertility treatments pose significant limitations, potentially restraining market growth. Even socio-cultural factors, including the stigma attached to fertility treatments, could dampen market adoption.

For innovation and business growth, focusing on research in precision medicine and the biochemical pathways of HCG to broaden its therapeutic applications could enhance market viability. Moreover, investing in cost-effective treatment methodologies and establishing strong collaborative networks among biotech firms, research institutes, and healthcare providers can extend market penetration. The nature of the HCG market is dynamic, with innovations in genetic research and biomanufacturing catalyzing potential evolution. Understanding consumer needs, leveraging emerging biotechnologies, and fostering ethical transparency can guide market actors towards sustainable growth and competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Chorionic Gonadotropin Market

The Human Chorionic Gonadotropin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidents of infertility among populations
    • Growing investments in the development of fertility clinics
    • Increasing awareness of fertility treatments
  • Market Restraints
    • High cost associated with human chorionic gonadotropin therapy
  • Market Opportunities
    • Advancements in recombinant technology
    • Emergence of gonadotropin therapy in the healthcare sector
  • Market Challenges
    • Possible side effects of human chorionic gonadotropin therapy

Porter's Five Forces: A Strategic Tool for Navigating the Human Chorionic Gonadotropin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Chorionic Gonadotropin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Chorionic Gonadotropin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Chorionic Gonadotropin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Chorionic Gonadotropin Market

A detailed market share analysis in the Human Chorionic Gonadotropin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Chorionic Gonadotropin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Chorionic Gonadotropin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Chorionic Gonadotropin Market

A strategic analysis of the Human Chorionic Gonadotropin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Naturally Extracted and Recombinant.
  • Based on Therapeutic Area, market is studied across Female Infertility Treatment, Male Hypogonadism, and Oligospermia Treatment.
  • Based on End-User, market is studied across Fertility Clinics and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidents of infertility among populations
      • 5.1.1.2. Growing investments in the development of fertility clinics
      • 5.1.1.3. Increasing awareness of fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with human chorionic gonadotropin therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in recombinant technology
      • 5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
    • 5.1.4. Challenges
      • 5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Chorionic Gonadotropin Market, by Product

  • 6.1. Introduction
  • 6.2. Naturally Extracted
  • 6.3. Recombinant

7. Human Chorionic Gonadotropin Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Female Infertility Treatment
  • 7.3. Male Hypogonadism
  • 7.4. Oligospermia Treatment

8. Human Chorionic Gonadotropin Market, by End-User

  • 8.1. Introduction
  • 8.2. Fertility Clinics
  • 8.3. Research Institutions

9. Americas Human Chorionic Gonadotropin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Chorionic Gonadotropin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biocare Medical, LLC
  • 2. Bristol Myers Squibb Company
  • 3. Cipla Limited
  • 4. Ferring B.V.
  • 5. Fresenius Kabi AG
  • 6. Intas Pharmaceuticals Ltd.
  • 7. Kamia Biomedical Company
  • 8. Lee Biosolutions, Inc.
  • 9. Life Medicare & Biotech Private Limited
  • 10. Livzon Pharmaceutical Group Inc.
  • 11. Lupin Limited
  • 12. Merck & Co., Inc.
  • 13. Prospec-Tany Technogene Ltd.
  • 14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
  • 15. Sanzyme ( P ) Ltd.
  • 16. Scripps Laboratories, Inc.
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Sunrise International Labs Ltd.

LIST OF FIGURES

  • FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY NATURALLY EXTRACTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FEMALE INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MALE HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OLIGOSPERMIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023